Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1291 to 1305 of 2042 results for guidelines

  1. What symptoms do children, young people, pregnant women and older people with suspected post‑COVID‑19 syndrome present with?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  2. Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)

    Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.

    Technology appraisal guidance
    Published
    15 June 2021
    View recommendations

    Sections for TA707

  3. Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

    Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    15 November 2017
    View recommendations

    Sections for TA488

  4. Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA180

  5. HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (MTG32)

    Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.

    Medical technologies guidance
    Last updated
    19 May 2021
    View recommendations

    Sections for MTG32

  6. What is the clinical effectiveness of D-dimer and other blood tests and clinical features as prognostic markers of developing post‑COVID‑19 syndrome?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  7. What pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised fatigue, breathlessness, and “brain fog”?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  8. Smart Peak Flow for monitoring asthma (MIB282)

    NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .

    Medtech innovation briefing
    Published
    11 January 2022

  9. Irreversible electroporation for treating prostate cancer (IPG768)

    Evidence-based recommendations on irreversible electroporation for treating prostate cancer. This involves using electrical pulses to destroy the cancer cells.

    Interventional procedures guidance
    Published
    5 July 2023
    View recommendations

    Sections for IPG768

  10. Coronary sinus narrowing device implantation for refractory angina (IPG712)

    Evidence-based recommendations on coronary sinus narrowing device implantation for refractory angina in adults. This involves putting a device into the coronary sinus to narrow it with the aim of improving the flow of oxygenated blood throughout the heart muscle.

    Interventional procedures guidance
    Published
    24 November 2021
    View recommendations

    Sections for IPG712

  11. Your voice is needed – my experience as a NICE committee member

    Dr Raja discusses the vital role frontline NHS colleagues have on our independent committees, and how you can get involved.

    News
    Last updated
    31 October 2024

  12. Radiation-induced lymphopenia and risk of new COVID-19 and severity of COVID-19: Does radiation-induced lymphopenia predispose patients to an increased risk of new COVID-19 and does it contribute to patients developing more severe COVID-19?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of radiotherapy Number NG162 Date issued

    Research recommendation
    Published
    21 October 2021

  13. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

    Medtech innovation briefing
    Published
    29 November 2016

  14. What is the prevalence and incidence of post-COVID-19 syndrome in patients who have received single, double, or boosted doses of the approved vaccinations in the UK? Does this vary across different population groups (for example in black, Asian and minority ethnic group communities)?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  15. Duration of risk of radiotherapy in people with cancer and COVID-19: Are people who have had radiotherapy recently (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of poor outcomes from COVID-19 compared with those who had radiotherapy less recently?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of radiotherapy Number NG162 Date issued

    Research recommendation
    Published
    21 October 2021